Treatment of Leukoplakia of Vagina in Squamous Cell Hyperplasia of the Vulva

Clinical Scenario

This protocol addresses leukoplakia of the vagina arising in the context of squamous cell hyperplasia of the vulva (SCHV). Along with vulvar lichen sclerosus, SCHV is recognised as one of the two principal non-neoplastic epithelial disorders of the vulva collectively referred to as vulvar leukoplakia.

Condition

Squamous cell hyperplasia of the vulva represents a distinct non-neoplastic epithelial disorder that must be appropriately characterised before treatment decisions are made. Its correct identification shapes the management approach and determines which interventions are appropriate.

Treatment Approach — Partial Overview

When conservative measures have been exhausted, the structured protocol includes guidance on surgical intervention as a last-resort option for selected cases — with specific procedures explicitly recommended against due to recurrence risk. The full decision algorithm, selection criteria, and sequencing are available in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.5114/pm.2020.99570

Two non-neoplastic epithelial disorders of the vulva – vulvar LS (VLS) and squamous cell hyperplasia of the vulva (SCHV) – are generally referred to as vulvar leukoplakia.

If all conservative treatment measures have failed, surgical treatment is indicated.

Surgical treatment of both diseases should be avoided because of recurrence risk and should only be used in certain cases, such as patients with malignancy, or to correct irreversible scarring, adhesions and micturition difficulties or sexual dysfunction caused by the subsequent anatomical changes.

However, vulvectomy and skinning vulvectomy should be avoided because of recurrence rates and disfigurement.

View source ↗